Ori Biotech Announces a $9.4M Seed Round to Advance Innovation in Cell and Gene Therapy ManufacturingHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Ori Biotech Announces a $9.4M Seed Round to Advance Innovation in Cell and Gene Therapy ManufacturingPR NewswireJanuary 9, 2020ReblogShareTweetShare- Syndicate includes leading UK investors Amadeus Capital Partners, Delin Ventures and Kindred Capital- Appoints Jason C. Foster as Chief Executive OfficerLONDON and PHILADELPHIA, Jan. 9, 2020 /PRNewswire/ -- Ori Biotech Ltd (Ori), an innovator in Cell and Gene Therapy (CGT) manufacturing, today announced that they successfully closed a $9.4M (£7M) seed round which will be used to bring their innovative manufacturing platform to market. The Ori platform will deliver scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.Founded by Dr. Farlan Veraitch and Prof. Chris Mason in 2015, Ori has designed a bespoke platform to specifically address the unique requirements of the new generation of personalised, living medicines. The investor syndicate is comprised of some of the UK's leading venture investors including Amadeus Capital Partners, Delin Ventures, Kindred Capital and a London-based family office, alongside a group of angel investors who have supported the company since inception.Jason C. Foster, newly appointed CEO of Ori Biotech said: "The successful financing underscores the potential of the Ori platform to fully automate cell and gene therapy manufacturing to increase throughput, improve quality and decrease costs. We look forward to collaborating with best-in-class suppliers, service providers and therapeutics developers to create next generation manufacturing solutions. We appreciate the support from our investors, and I am honored to join a company that has the potential to positively impact millions of lives by enabling patient access to these lifesaving treatments.""Hundreds of clinical trials and a few recently marketed products have shown the revolutionary potential of CGTs. But this potential will never be realised unless we can remove the current bottleneck around scalable manufacturing. Ori Biotech has developed an innovative platform technology to facilitate scalable manufacturing that could eventually enable millions of patients to get access to the next generation of personalised medicines," commented Dr Alan Barge, ex-Head of Oncology at AstraZeneca, Venture Partner at Delin Ventures and Non-Executive Director of Ori Biotech.Dr Farlan Veraitch, Co-Founder and Chief Scientific Officer of Ori Biotech added, "The challenges of providing high throughput, high quality and cost-effective CGT manufacturing are well documented in the industry and in publications by global regulatory authorities like the US FDA. By pioneering a completely novel hardware and software platform approach, we can help the CGT industry accelerate the delivery of these transformative therapies to patients in need."Ori Biotech at JP Morgan Healthcare Conference, San FranciscoThe Ori Biotech team will be at the 38th Annual J.P. Morgan Healthcare Conference on 13-16 January 2020 in San Francisco, California.Please get in touch if you would like to set up a meeting, details below.About Ori BiotechOri Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr. Farlan Veraitch and Prof. Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies.For more information, contact:Ori Biotech Jason C. Foster, CEO jasonfoster@oribiotech.com www.OriBiotech.comOptimum Strategic Communications Supriya Mathur, Shabnam BashirOptimum Communications+44-20-3922-0891oribiotech@optimumcomms.comCisionMoreView original content:http://www.prnewswire.com/news-releases/ori-biotech-announces-a-9-4m-seed-round-to-advance-innovation-in-cell-and-gene-therapy-manufacturing-300983736.htmlSOURCE Ori BiotechReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextWhy This Small Gene Therapy Player Rocketed On A Biogen DealInvestor's Business DailySarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss EstimatesZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoCanada Stock Bourse Says Ready for Friday Open After Early CloseBloomberg'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoIs Link Administration Holdings Limited (ASX:LNK) Trading At A 50% Discount?Simply Wall St.Richard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance